NCT04924192 is a Phase 2 clinical trial of TQB3616 capsules in Advanced Lung Carcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Who is sponsoring NCT04924192?

NCT04924192 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What drugs are being tested in NCT04924192?

Interventions in NCT04924192: TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection.

What condition does NCT04924192 study?

NCT04924192 studies Advanced Lung Carcinoma.

Is NCT04924192 still recruiting?

NCT04924192 is currently terminated. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT04924192

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Terminated Phase 2 Last updated 13 April 2026

What this trial tests

Phase 2 trial testing TQB3616 capsules in Advanced Lung Carcinoma in 21 participants. Terminated before completion.

Timeline

18 August 2021

Primary endpoint
27 September 2022

10 October 2022

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	18 August 2021
Primary completion	27 September 2022
Estimated completion	10 October 2022
Sites	7 locations across China

Drugs / interventions tested

TQB3616 capsules — full drug profile →
Anlotinib Hydrochloride capsules — full drug profile →
Irinotecan Hydrochloride for Injection — full drug profile →

Conditions studied

Advanced Lung Carcinoma — all drugs for Advanced Lung Carcinoma →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Advanced Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.
Safaroghli-Azar A, Mekonnen LB, Lenjisa J, Milne R, et al · · 2026 · PMID 41943159 · DOI 10.1186/s13045-026-01794-7

Verify or expand the search:

Other trials of TQB3616 capsules

Trials testing the same drug.

NCT05375461 — TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical T · Phase 3 · completed
NCT04796623 — A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer · Phase 2 · completed

Other recruiting trials for Advanced Lung Carcinoma

Currently open trials in the same condition.

NCT05705492 — Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancre · Phase 2 · recruiting
NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · Phase 2 · recruiting
NCT04819997 — A Nurse-Led Intervention for Fear of Progression in Advanced Cancer · NA · active not recruiting
NCT03707938 — Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer · Phase 1 · active not recruiting

Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials

Trials by the same sponsor.

NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04924192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04924192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing